TGTaranjit S. Gujral

Taranjit S. Gujral

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taranjit S. Gujral has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Aleena K. S. Arakaki

    Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA

    1 shared publication
  • Eric C. Holland

    Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

    1 shared publication
  • Helen Wedegaertner

    Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA

    1 shared publication
  • Ivette Roca-Mercado

    Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA

    1 shared publication
  • JoAnn Trejo

    Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA

    1 shared publication
  • Logan Chinn

    Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA

    1 shared publication

Latest Publications

  • Open Access

    α-Arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis

    by Aleena K. S. Arakaki, Wen-An Pan, Helen Wedegaertner, Ivette Roca-Mercado, Logan Chinn, Taranjit S. Gujral, JoAnn Trejo

    The α-arrestin domain containing protein 3 (ARRDC3) is a tumor suppressor in triple-negative breast carcinoma (TNBC), a highly metastatic subtype of breast cancer that lacks targeted therapies. Thus, understanding the mechanisms and targets of ARRDC3 in TNBC is important. ARRDC3 regulates trafficking of protease-activated receptor 1 (PAR1, also known as F2R), a G-protein-coupled receptor (GPCR) implicated in breast cancer metastasis. Loss of ARRDC3 causes overexpression of PAR1 and aberrant signaling. Moreover, dysregulation of GPCR-induced Hippo signaling is associated with breast cancer progression. However, the mechanisms responsible for Hippo dysregulation remain unknown. Here, we report that the Hippo pathway transcriptional co-activator TAZ (also known as WWTR1) is the major effector of GPCR signaling and is required for TNBC migration and invasion. Additionally, ARRDC3 suppresses PAR1-induced Hippo signaling via sequestration of TAZ, which occurs independently of ARRDC3-regulated PAR1 trafficking. The ARRDC3 C-terminal PPXY motifs and TAZ WW domain are crucial for this interaction and are required for suppression of TNBC migration and lung metastasis in vivo. These studies are the first to demonstrate a role for ARRDC3 in regulating GPCR-induced TAZ activity in TNBC and reveal multi-faceted tumor suppressor functions of ARRDC3. This article has an associated First Person interview with the first author of the paper.


  • Open Access

    Machine Learning Identifies Ponatinib as a Potent Inhibitor of SARS-CoV2-induced Cytokine Storm

    by Marina Chan, Siddharth Vijay, M. Juliana McElrath, Eric C. Holland, Taranjit S Gujral

    Although 15-20% of COVID-19 patients experience hyper-inflammation induced by massive cytokine production, cellular triggers of this process and strategies to target them remain poorly understood. Here, we show that the N-terminal domain (NTD) of the spike protein from the SARS-CoV-2 and emerging variants B1.1.7 and B.1.351 substantially induces multiple inflammatory molecules in human monocytes and PBMCs. Further, we identified several protein kinases, including JAK1, EPHA7, IRAK1, MAPK12, and MAP3K8, as essential downstream mediators of NTD-induced cytokine release. Additionally, we found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the NTD-mediated cytokine storm. Taken together, we propose that agents targeting multiple kinases required for the SARS-CoV-2-mediated cytokine storm, such as Ponatinib, may represent an attractive therapeutic option for treating moderate to severe COVID-19.